Meiji Holdings Co., Ltd. Meiji Holdings Co., Ltd. Financial Results - For the FYE March 2016 -  


Pharma: Offset NHI Drug Price Revisions to Achieve Further Growth

Prev. Page Next Page Download the PDF
Pharmaceutical segment
 Offset 9.2 billion yen in incomes losses due to NHI price revisions to continue growth.

Domestic ethical pharmaceuticals
 Maintaining strong presence with No. 2 share for both systemic antibacterial drugs and antidepressant drugs
 Release new drugs in areas of strength for both brand-name and generic markets.
  -Sycrest, antipsychotic drug, is scheduled for release in May.
  -Anti-allergy drug, COPD drugs
  -Enhance generic lineup
 Promote those new drugs together with existing products and maximize the first year sales.

Agrochemical and veterinary drugs
 Accelerate selection and concentration and improve profitability break-even
 Continue structural reforms to establish a stable profit structure